口腔癌肿瘤微环境中肿瘤浸润 B 细胞的丰富度是早期疾病的预后因素并可改善晚期疾病的结局

In total, 222 OCSCCs were studied. Consecutive sections were stained for CD45 and CD19. OCSCCs were categorized as either "TIL-B-rich" or "TIL-B-poor", and the survival of both groups was analyzed. Similar analyses were performed for CD45+ TILs and the CD19/CD45 ratio. Matched subgroups of twelve TIL-B-rich and TIL-B-poor tumors were stained for CD3 and CD8 to determine differences in T-cell infiltration, and further spatial interaction between T- and B-cells was evaluated in six samples.

Five-year OS was 75.0% for TIL-B-rich and 54.2% for TIL-B-poor OCSCCs ( p < 0.001). The survival benefit of TIL-B-rich OCSCCs remained significant after correction for the histopathological characteristics ( p = 0.033). While for early-stage tumors, TIL-B richness benefited OS independent of demographic-, clinical, or histopathological features, for advanced-stage disease, this was not the case, although a clear benefit of a TIL-B-rich status was observed, specifically up until 36 months after diagnosis. TIL-B-rich tumors contained more CD3+ TILs ( p = 0.007), but not CD8+ TILs. Spatial characterization suggested that TIL-Bs mostly co-localized with CD3+CD8- TILs and that this interaction was increased in TIL-B-rich OCSCC.

The presence of TIL-Bs is associated with a more favorable prognosis in OCSCC, in particular for early-stage disease.